Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$14.26Cboe Real-Time Last Sale as of 2:37PM ET 3/30/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.28(2.00%)
Bid (Size)$14.22 (100)
Ask (Size)$14.27 (100)
Day Low / High$13.42 - 14.59
Volume935.8 K

View Biotechnology IndustryPeer Comparison as of 03/30/2020


Aimmune Therapeutics Inc ( NASDAQ )

Price: $14.26
Change: +0.28 (2.00%)
Volume: 935.8 K
2:37PM ET 3/30/2020

Adverum Biotechnologies Inc ( NASDAQ )

Price: $11.07
Change: -0.36 (3.15%)
Volume: 228.5 K
2:37PM ET 3/30/2020

Akebia Therapeutics Inc ( NASDAQ )

Price: $7.71
Change: +0.66 (9.36%)
Volume: 726.5 K
2:32PM ET 3/30/2020

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $13.34
Change: +0.26 (1.99%)
Volume: 120.2 K
2:34PM ET 3/30/2020

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $49.74
Change: +2.71 (5.76%)
Volume: 72.7 K
2:37PM ET 3/30/2020

Read more news Recent News

Insider Trends: Insider Buying Extended with Purchase of AIMSI Technologies Stock
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, made a purchase of 125,000 shares in AIMSI Technologies (AIMT) on Mar 17, 2020, for $1,420,045. After the Form 4 filing with...

Insider Trends: Insider Purchase Adds to Aimmune Therapeutics Positive Trend
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, on Mar 17, 2020, executed a purchase for 125,000 shares in Aimmune Therapeutics (AIMT) for $1,420,045. Enright has control...

--Analyst Actions: JMP Securities Downgrades Aimmune Therapeutics to Market Perform From Market Outperform
9:52AM ET 3/18/2020 MT Newswires

Price: 11.09, Change: -0.42, Percent Change: -3.65 ...

Aimmune Therapeutics Says First Patients in US Being Treated With Peanut Allergy Drug Palforzia
11:18AM ET 3/16/2020 MT Newswires

Aimmune Therapeutics (AIMT) announced Monday the first US patients being treated with Palforzia for peanut allergy. The drug, which was approved by the US...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Number of Employees215
Recent SEC Filing03/19/20204
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric Hands Claude Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Senior VP-Corporate Development & StrategyMary M. Rozenman

Company Highlights

Price Open$14.00
Previous Close$13.98
52 Week Range$10.09 - 37.00
Market Capitalization$893.6 M
Shares Outstanding62.7 M
SectorHealth Technology
Next Earnings Announcement05/13/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.97
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-138.44%

Analyst Ratings as of 03/17/2020

Consensus RecommendationConsensus Icon
Powered by Factset